Last reviewed · How we verify
Alfarol (ALFACALCIDOL)
Alfarol (generic name: ALFACALCIDOL) is a alfacalcidol drug. It is currently in discontinued development for Hyperparathyroidism, Hypoparathyroidism, Neonatal hypocalcemia.
Alfarol works by activating vitamin D receptors in the body, which helps regulate calcium levels.
Alfarol is a medication used to treat osteoporosis. It is administered in a dose of 1.0 µg.
At a glance
| Generic name | ALFACALCIDOL |
|---|---|
| Drug class | alfacalcidol |
| Target | Sodium-dependent noradrenaline transporter |
| Modality | Small molecule |
| Therapeutic area | Nephrology |
| Phase | discontinued |
Mechanism of action
Think of vitamin D like a key that unlocks the body's ability to absorb calcium from food. When vitamin D is activated, it helps the body use calcium to build strong bones and teeth, and also helps the body absorb calcium from the food we eat.
Approved indications
- Hyperparathyroidism
- Hypoparathyroidism
- Neonatal hypocalcemia
- Renal osteodystrophy
Common side effects
- Muscle spasticity
- Ear pain
- Respiratory disorder
- Body temperature increased
- Night sweats
- Hypocalcaemia
- Shunt stenosis
- Lower respiratory tract infection
- Hypercalcaemia
- Urticaria
- Shunt occlusion
- Renal impairment
Key clinical trials
- Assessment of the Locally Administrated Vitamin D3 and Corticision Efficacy on Orthodontic Canine Retraction (NA)
- Effects of Total Thyroid Removal on Parathyroid Function and Quality of Life (NA)
- Pentoxifylline on Inflammatory Markers in Non-Diabetic Chronic Kidney Disease Patients (NA)
- Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1 (PHASE3)
- Active Vitamin D And Reduced Dose Prednisolone for Treatment in Minimal Change Nephropathy (PHASE4)
- The Role of VitD in Rehabilitation of Idiopathic Adolescent Scoliosis (PHASE2)
- Vitamin D in Dialysis Patients - Diagnostic and Therapeutic Management
- A Study on the Prevention and Treatment of GIOP With Eldecalcitol (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Alfarol CI brief — competitive landscape report
- Alfarol updates RSS · CI watch RSS
Frequently asked questions about Alfarol
What is Alfarol?
How does Alfarol work?
What is Alfarol used for?
What is the generic name of Alfarol?
What drug class is Alfarol in?
What development phase is Alfarol in?
What are the side effects of Alfarol?
What does Alfarol target?
Related
- Drug class: All alfacalcidol drugs
- Target: All drugs targeting Sodium-dependent noradrenaline transporter
- Therapeutic area: All drugs in Nephrology
- Indication: Drugs for Hyperparathyroidism
- Indication: Drugs for Hypoparathyroidism
- Indication: Drugs for Neonatal hypocalcemia
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing